Positioning of axitinib/axitinib in treatment options

Axitinib/Axitinib is an oral small molecule targeted drug widely used to treat advanced renal cell carcinoma (RCC). Based on current clinical studies and treatment guidelines, axitinib is generally considered a second-line treatment option, especially after patients have developed resistance to other systemic treatments, such as immunotherapy or other targeted therapies. However, studies in recent years have also gradually explored its potential application in first-line treatment.

In first-line treatment, axitinib can be used in combination with immune checkpoint inhibitors, such as avelumab or pembrolizumab, in order to improve the therapeutic effect. This combination treatment regimen has shown potential to improve progression-free survival and overall survival in certain patient populations. Therefore, axitinib's status in first-line treatment is increasingly recognized, providing new treatment options for more patients with advanced renal cell carcinoma.

As a second-line treatment, axitinib has clearer indications. Axitinib can be an effective follow-up treatment option for patients whose disease has progressed despite other treatments, such as classic targeted therapies such as sorafenib or sunitinib. Its mechanism of action is mainly by inhibiting vascular endothelial growth factor (VEGF) receptors, thereby reducing the blood supply of tumors and inhibiting tumor growth and metastasis.

Clinical trials have shown that axitinib has significant efficacy in patients with advanced renal cell carcinoma, and its side effects are relatively controllable. Common adverse reactions include hypertension, fatigue, diarrhea, and stomatitis, which can often be alleviated with appropriate management and supportive care. When using axitinib, doctors will make individualized dose adjustments based on the patient's specific conditions to achieve the best therapeutic effect.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84137882-e000-47da-bd5b-fa76ab3c76f9##